{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:41:00Z","timestamp":1794606060659,"version":"4.9.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"International FOP Association ACT"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","award":["R01AR073015"],"award-info":[{"award-number":["R01AR073015"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSF Robert Kroc Chair in Connective Tissue and Rheumatic Diseases III"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Fibrodysplasia ossificans progressiva (FOP) is one of the most catastrophic forms of genetic heterotopic ossification (HO). FOP is characterized by severe, progressive inflammatory flare-ups, that often lead to HO. The flare-ups are associated with increased inflammatory cytokine production, suggesting auto-inflammatory features driven by IL-1\u03b2. This study describes the short- and long-term responses of FOP patients to anti-IL-1 therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Previously, we reported that a patient with FOP treated with anti-IL-1 agents showed dramatically lower rates of flare-ups, improved flare-up symptoms, decreased use of glucocorticoids and apparently decreased size of residual lesions. Plasma analyses also showed marked elevation in IL-1\u03b2 levels during a FOP flare, further supporting a role of IL-1\u03b2 in the pathogenesis of FOP flares. Here, we report results from long-term therapy with IL-1 inhibitors in that patient and describe 3 additional patients, from two medical centres.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 4 patients showed persistent improvement in flare activity during treatment with IL-1 inhibitors, with minimal formation of new HO sites. Two patients who stopped therapy experienced a resurgence of flare activity that was re-suppressed upon re-initiation. These patients had IL-1\u03b2 levels comparable to those in IL-1\u03b2-driven diseases. Child Health Assessment Questionnaires confirmed extensive subjective improvements in the pain and general health visual analogue scales.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This case series demonstrates significant benefits from IL-1 inhibitors for reducing flare activity and improving the general health of patients with FOP. These data provide strong support for additional studies to better understand the function of IL-1 inhibition, primarily in reducing the formation of new HO.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>RH received support from the International FOP Association ACT grant; ECH received support from NIH\/NIAMS R01AR073015 and the UCSF Robert Kroc Chair in Connective Tissue and Rheumatic Diseases III.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae255","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T12:18:47Z","timestamp":1715343527000},"page":"2597-2604","source":"Crossref","is-referenced-by-count":11,"title":["Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-1939","authenticated-orcid":false,"given":"Ruby","family":"Haviv","sequence":"first","affiliation":[{"name":"Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center , Kfar Saba, Israel"},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel"},{"name":"Pediatric Orthopedic Department, Dana-Dwek Children's Hospital, Sourasky Medical Center , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Moshe","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center , Kfar Saba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Ziv","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center , Kfar Saba, Israel"},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Rabinowicz","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center , Kfar Saba, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Bambino Ges\u00f9 Children\u2019s Hospital IRCCS , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusi","family":"Prencipe","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Bambino Ges\u00f9 Children\u2019s Hospital IRCCS , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Matteo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Bambino Ges\u00f9 Children\u2019s Hospital IRCCS , Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Laura","family":"De Cunto","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Pediatrics, Hospital Italiano de Buenos Aires , Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Institute for Human Genetics, The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Department of Medicine, University of California , San Francisco, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Uziel","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center , Kfar Saba, Israel"},{"name":"School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"2024090322075628800_keae255-B1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13023-021-01983-2","article-title":"Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization","volume":"16","author":"Pignolo","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"2024090322075628800_keae255-B2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13023-019-1068-7","article-title":"Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes","volume":"14","author":"Pignolo","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2024090322075628800_keae255-B3","doi-asserted-by":"crossref","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","article-title":"ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A","volume":"7","author":"Hatsell","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024090322075628800_keae255-B4","first-page":"1","article-title":"The medical management of fibrodysplasia ossificans progressiva: current treatment considerations","volume":"2","author":"Kaplan","year":"2021","journal-title":". Proc Intl Clin Council FOP"},{"key":"2024090322075628800_keae255-B5","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00256-018-2889-5","article-title":"Fibrodysplasia ossificans progressiva: a current review of imaging findings","volume":"47","author":"Bauer","year":"2018","journal-title":"Skeletal Radiol"},{"key":"2024090322075628800_keae255-B6","doi-asserted-by":"crossref","first-page":"e122958","DOI":"10.1172\/jci.insight.122958","article-title":"NF-kappaB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification","volume":"3","author":"Barruet","year":"2018","journal-title":"JCI Insight"},{"key":"2024090322075628800_keae255-B7","doi-asserted-by":"crossref","first-page":"116129","DOI":"10.1016\/j.bone.2021.116129","article-title":"ACVR1(R206H) extends inflammatory responses in human induced pluripotent stem cell-derived macrophages","volume":"153","author":"Matsuo","year":"2021","journal-title":"Bone"},{"key":"2024090322075628800_keae255-B8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11914-019-00541-x","article-title":"Inflammation in fibrodysplasia ossificans progressiva and other forms of heterotopic ossification","volume":"17","author":"Matsuo","year":"2019","journal-title":"Curr Osteopor Rep"},{"key":"2024090322075628800_keae255-B9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1385\/BMM:3:3-4:189","article-title":"Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway","volume":"3","author":"Kaplan","year":"2005","journal-title":"Clinic Rev Bone Miner Metab"},{"key":"2024090322075628800_keae255-B10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2106\/JBJS.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan","year":"2010","journal-title":"J Bone Joint Surg"},{"key":"2024090322075628800_keae255-B11","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.jaut.2020.102421","article-title":"Systemic autoinflammatory diseases","volume":"109","author":"Krainer","year":"2020","journal-title":"J Autoimmun"},{"key":"2024090322075628800_keae255-B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00223-016-0139-1","article-title":"Interleukin-1\u03b2 suppresses the transporter genes Ank and Ent1 expression in stromal progenitor cells retaining mineralization","volume":"99","author":"Ezura","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"2024090322075628800_keae255-B13","doi-asserted-by":"crossref","first-page":"29494","DOI":"10.1074\/jbc.M113.471268","article-title":"Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow","volume":"288","author":"Ferreira","year":"2013","journal-title":"J Biol Chem"},{"key":"2024090322075628800_keae255-B14","first-page":"236","article-title":"Experimental heterotopic bone formation induced by bone morphogenetic protein and recombinant human interleukin-1 \u03b2","author":"Mahy","year":"1988","journal-title":"Clin Orthop Relat Res"},{"key":"2024090322075628800_keae255-B15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12969-019-0386-6","article-title":"Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?","volume":"17","author":"Haviv","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024090322075628800_keae255-B16","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.gim.2022.08.013","article-title":"The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study","volume":"24","author":"Pignolo","year":"2022","journal-title":"Genet Med"},{"key":"2024090322075628800_keae255-B17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/jbmr.4762","article-title":"Reduction of new heterotopic ossification (HO) in the Open-Label, Phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP)","volume":"38","author":"Pignolo","year":"2022","journal-title":"J Bone Mineral Res"},{"key":"2024090322075628800_keae255-B18","doi-asserted-by":"crossref","first-page":"116016","DOI":"10.1016\/j.bone.2021.116016","article-title":"Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva","volume":"150","author":"Kaplan","year":"2021","journal-title":"Bone"},{"key":"2024090322075628800_keae255-B19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2022.05.038","article-title":"Massive cervical heterotopic ossification and extra-articular temporomandibular joint ankylosis","volume":"248","author":"Haviv","year":"2022","journal-title":"J Pediatr"},{"key":"2024090322075628800_keae255-B20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20082481","article-title":"In vivo regulation of interleukin 1\u03b2 in patients with cryopyrin-associated periodic syndromes","volume":"206","author":"Lachmann","year":"2009","journal-title":"J Exp Med"},{"key":"2024090322075628800_keae255-B21","first-page":"397","article-title":"Pharmacokinetics and pharmacodynamics of canakinumab in patients with autoinflammatory periodic fever syndromes (colchicine resistant FMF, HIDS\/MKD and traps)","volume":"75","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024090322075628800_keae255-B22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMoa1706314","article-title":"Canakinumab for the treatment of autoinflammatory recurrent fever syndromes","volume":"378","author":"De Benedetti","year":"2018","journal-title":"N Engl J Med"},{"key":"2024090322075628800_keae255-B23","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab.in the cryopyrin-associated periodic syndrome","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"2024090322075628800_keae255-B24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13023-020-01406-8","article-title":"Prophylactic treatment of rapamycin ameliorates naturally developing and episode-induced heterotopic ossification in mice expressing human mutant ACVR1","volume":"15","author":"Maekawa","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2024090322075628800_keae255-B25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12891-022-05471-x","article-title":"Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)","volume":"23","author":"Smilde","year":"2022","journal-title":"BMC Musculoskeletal Disord"},{"key":"2024090322075628800_keae255-B26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jcph.1638","article-title":"Pharmacokinetics and pharmacodynamics of Garetosmab (Anti-Activin A): results from a First-in-Human Phase 1 Study","volume":"60","author":"Vanhoutte","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2024090322075628800_keae255-B27","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12969-023-00856-1","article-title":"Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva","volume":"21","author":"Nikishina","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"2024090322075628800_keae255-B28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-018-1685-x","article-title":"Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils","volume":"20","author":"Furuya","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2024090322075628800_keae255-B29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00296-019-04490-7","article-title":"Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review","volume":"40","author":"Karadeniz","year":"2020","journal-title":"Rheumatol Int"},{"key":"2024090322075628800_keae255-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","article-title":"A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP)","volume":"101","author":"Kaplan","year":"2017","journal-title":"Bone"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae255\/57824540\/keae255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2597\/59007301\/keae255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2597\/59007301\/keae255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T10:45:42Z","timestamp":1725446742000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2597\/7669118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,5,11]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae255","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,5,11]]}}}